Dicerna Pharmaceuticals, Inc (DRNA)

Etorro trading 970x250
Dicerna Pharmaceuticals, Inc (DRNA) Logo

About Dicerna Pharmaceuticals, Inc

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Address: 75 Hayden Avenue, Lexington, MA, United States, 02421

Dicerna Pharmaceuticals, Inc News and around…

Latest news about Dicerna Pharmaceuticals, Inc (DRNA) common stock and company :

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
28 Dec, 2021 FinancialContent

Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
25 Dec, 2021 FinancialContent

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

MainStay VP Wellington Small Cap Portfolio Buys iShares Russell 2000 Growth ETF, United Natural ...
23 Dec, 2021 Yahoo! Finance

Investment company MainStay VP Wellington Small Cap Portfolio (Current Portfolio) buys iShares Russell 2000 Growth ETF, United Natural Foods Inc, Mimecast, Insperity Inc, Chesapeake Energy Corp, sells Ollie's Bargain Outlet Holdings Inc, Apellis Pharmaceuticals Inc, Children's Place Inc, Hostess Brands Inc, Boston Beer Co Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Wellington Small Cap Portfolio.

Noteworthy ETF Outflows: XBI, CCXI, DRNA, ARNA
16 Dec, 2021 FinancialContent

Symbols mentioned in this story: XBI, CCXI, DRNA, ARNA Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA
14 Dec, 2021 Yahoo! Finance

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration

Hedge Funds Are Selling Dicerna Pharmaceuticals Inc (DRNA)
13 Dec, 2021 Yahoo! Finance

Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - ROG, PAE, MNTV, CSPR, VLY, DRNA
09 Dec, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

10 Biggest Price Target Changes For Thursday
09 Dec, 2021 FinancialContent

SVB Leerink boosted the price target on Edwards Lifesciences Corporation (NYSE: EW) from $130 to $135. Edwards Lifesciences shares ...

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
09 Dec, 2021 FinancialContent

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform. BMO ...

Direxion Launches mRNA ETF (MSGR)
09 Dec, 2021 Yahoo! Finance

Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.

SHAREHOLDER ALERT: WeissLaw LLP Reminds VG, DRNA, DVD, and COR Shareholders About Its Ongoing Investigations
08 Dec, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADTN, ROG, VG, DRNA; Shareholders are Encouraged to Contact the Firm
04 Dec, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Dicerna Pharmaceuticals, Inc. Corporation (Nasdaq – DRNA)
03 Dec, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / December 3, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (Nasdaq:DRNA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Novo Nordisk, in an all-cash transaction with a total value of approximately $3.

SHAREHOLDER ALERT: WeissLaw LLP Reminds STXB, DRNA, DVD and VSAT Shareholders About Its Ongoing Investigations
03 Dec, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Moore Kuehn Encourages ASPC, ROG, DRNA, and VG Investors to Contact Law Firm
02 Dec, 2021 Yahoo! Finance

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Alpha Capital Acquisition Company (NASDAQ: ASPC) Alpha Capital has agreed to merge with Semantix

Notable ETF Outflow Detected - XBI, CCXI, DRNA, MCRB
29 Nov, 2021 FinancialContent

Symbols mentioned in this story: XBI, CCXI, DRNA, MCRB Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CONE, VLY, DRNA, CSPR; Shareholders are Encouraged to Contact the Firm
26 Nov, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SHAREHOLDER ALERT: WeissLaw LLP Reminds DRNA, IHC, NE, and ABTX Shareholders About Its Ongoing Investigations
24 Nov, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
23 Nov, 2021 FinancialContent

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COR, STXB, BCML, DRNA; Shareholders are Encouraged to Contact the Firm
23 Nov, 2021 FinancialContent
ACT NOW: Monteverde & Associates PC Continues to Investigate the Following Acquisition
22 Nov, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) relating to its proposed acquisition by Novo Nordisk.

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Dicerna Pharmaceuticals, Inc. Corporation (Nasdaq – DRNA), Rogers Corporation (NYSE - ROG), Independence Holding Company (NYSE – IHC)
22 Nov, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / November 22, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA
22 Nov, 2021 Yahoo! Finance

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Dicerna Pharmaceuticals, Inc. ("DRNA" or the "Company") (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DRNA, RRD, LEVL, HRC; Shareholders are Encouraged to Contact the Firm
22 Nov, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
19 Nov, 2021 FinancialContent

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

54 Biggest Movers From Yesterday
19 Nov, 2021 FinancialContent

Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare ...

Noteworthy Thursday Option Activity: DISCK, APO, DRNA
18 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Discovery Inc - Series C (DISCK), where a total volume of 70,963 contracts has been traded thus far today, a contract volume which is representative of approximately 7.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 221% of DISCK's average daily trading volume over the past month, of 3.2 million shares..

Mid-Afternoon Market Update: Dow Falls 75 Points; Dicerna Pharmaceuticals Shares Spike Higher
18 Nov, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.21% to 35,855.96 while the NASDAQ rose 0.16% to 15,946.49. The S&P also ...

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
18 Nov, 2021 FinancialContent

Novartis AG(NYSE: NVS) is getting a massive influx of cash fromselling its 20-year stakeinRoche Holdings ...

Rivian Plunges, but This Under-the-Radar Nasdaq Stock Is Soaring
18 Nov, 2021 FinancialContent

Find out what took two stocks listed on the Nasdaq in different directions on Thursday.

Dicerna Pharmaceuticals, Inc (DRNA) is a NASDAQ Common Stock listed in , ,

970x250